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enBACKGROUND Treatment of patients with drug-eluting stent (DES) in-stent restenosis (ISR) remains a major
challenge.
OBJECTIVES This study evaluated the comparative efﬁcacy of drug-eluting balloons (DEB) and everolimus-eluting
stents (EES) in patients presenting with DES-ISR.
METHODS The study design of this multicenter randomized clinical trial assumed superiority of EES for the primary
endpoint, in-segment minimal lumen diameter at the 6- to 9-month angiographic follow-up.
RESULTS A total of 309 patients with DES-ISR from 23 Spanish university hospitals were randomly allocated to DEB
(n ¼ 154) or EES (n ¼ 155). At late angiography (median 247 days; 90% of eligible patients), patients in the EES arm had a
signiﬁcantly larger minimal lumen diameter (2.03  0.7 mm vs. 1.80  0.6 mm; p < 0.01) (absolute mean difference:
0.23 mm; 95% CI: 0.07 to 0.38), net lumen gain (1.28  0.7 mm vs. 1.01  0.7 mm; p < 0.01), and lower percent
diameter stenosis (23  22% vs. 30  22%; p < 0.01) and binary restenosis rate (11% vs. 19%; p ¼ 0.06), compared with
patients in the DEB arm. Consistent results were observed in the in-lesion analysis. At the 1-year clinical follow-up (100%
of patients), the main clinical outcome measure (composite of cardiac death, myocardial infarction, and target vessel
revascularization) was signiﬁcantly reduced in the EES arm (10% vs. 18%; p ¼ 0.04; hazard ratio: 0.58; 95% CI: 0.35 to
0.98), mainly driven by a lower need for target vessel revascularization (8% vs. 16%; p ¼ 0.035).
CONCLUSIONS In patients with DES-ISR, EES provided superior long-term clinical and angiographic results compared
with DEB. (Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloon vs Everolimus-Eluting Stent [RIBS IV];
NCT01239940) (J Am Coll Cardiol 2015;66:23–33) © 2015 by the American College of Cardiology Foundation.m the *Hospital Universitario de La Princesa, Madrid, Spain; yHospital Universitario Clínico San Carlos, Madrid, Spain;
ospital Universitario Vall d’Hebron, Barcelona, Spain; xHospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain;
ospital Universitario Infanta Cristina, Badajoz, Spain; {Hospital Universitario Clinic de Barcelona, Barcelona, Spain; #Hospital
iversitario Marqués de Valdecilla, Santander, Spain; **Hospital Universitario de Meixoeiro, Vigo, Spain; yyHospital Universitario
de Octubre, Madrid, Spain; zzHospital Universitario La Paz, Madrid, Spain; xxHospital Universitario de Alicante, Alicante, Spain;
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AND ACRONYMS
BMS = bare-metal stent(s)
DEB = drug-eluting balloon(s)
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
ISR = in-stent restenosis
MI = myocardial infarction
MLD = minimal lumen diameter
SES = sirolimus-eluting
stent(s)
TLR = target lesion
revascularization
TVR = target vessel
revascularization
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24D rug-eluting stents (DES) are widelyused to treat ischemic coronary ar-tery disease. Their dramatic ability
to inhibit neointimal proliferation clinically
translates into a signiﬁcantly reduced need
for repeat revascularization (1,2). Rarely
DES may develop in-stent restenosis (ISR),
especially when used in complex clinical
and anatomic scenarios (3,4). Importantly,
treatment of DES-ISR remains challenging.
Several studies have demonstrated that
angiographic and clinical outcomes of pa-
tients treated for DES-ISR are poorer than
those found in patients with bare-metal stent
(BMS) ISR (3–7). Indeed, the therapy of
choice for patients with DES-ISR remains un-
settled (3,4). Data from controlled clinical tri-als suggest that repeat DES implantation constitutes
an attractive therapeutic strategy in this setting
(7–10). Alternatively, drug-eluting balloons (DEB)
also provide excellent late angiographic and clinical
outcomes in patients with either BMS- or DES-ISR
(11–18). In these patients, DEB are superior to conven-
tional balloon angioplasty and at least similar to ﬁrst-
generation DES (11–18).SEE PAGE 34Second-generation DES are safer and more effec-
tive than ﬁrst-generation DES (19,20). In particular,
recent studies have shown uniquely favorable long-
term results in patients treated with everolimus-
eluting stents (EES) (19,20). The value of newer DES
has also been demonstrated in complex lesion sub-
sets, including BMS-ISR and DES-ISR (21). However,
the relative efﬁcacy of second-generation DES versus
DEB in patients with DES-ISR remains unsettled.
METHODS
The RIBS IV (Restenosis Intra-Stent of Drug-Eluting
Stents: Drug-Eluting Balloon vs Everolimus-Eluting
Stent) study is a prospective multicenter, open-label,
controlled, randomized clinical trial comparing DEB
and EES in patients with DES-ISR (Online Appendix).
The study protocol was published previously (22). In-
clusion and exclusion criteria were similar to those ofwas exclusively performed by the investigators. There was an u
support this study. These companies, however, played no role
riting of the report, or the decision to submit it for publication
ll other authors have reported that they have no relationships re
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
received February 5, 2015; revised manuscript received April 17,previous RIBS trials (7,8,18,21). Eligible patients pre-
sented with angina or objective evidence of ischemia
and showed DES-ISR on angiography (>50% diameter
stenosis on visual assessment). Any type of DES pre-
senting ISR was eligible, but patients in whom stent
type could not be identiﬁed and those with unclear
stent location were excluded. Patients with small
vessels (#2.0 mm in diameter), very long lesions
(>30 mm in length), or total occlusions (Thrombolysis
In Myocardial Infarction ¼ 0) were also excluded
(7,8,18,21). To avoid the possibility of including pa-
tients with stent thrombosis, patients with very early
(<1 month) DES-ISR, those presenting with acute
myocardial infarction (MI), or those with obvious
angiographic thrombus were excluded. However, pa-
tients with multiple interventions at the target lesion,
including those with >1 stent layer, were eligible. Pa-
tients with edge-ISR were only included when stent-
edge involvement could be demonstrated. In this
regard, the use of multiple angulated angiographic
images was recommended to establish the relation-
ship between the lesion and stent border. In addition,
the study protocol suggested intracoronary imaging to
conﬁrm stent edge involvement. Patients with nar-
rowing affecting the DES margin and extending into
the adjacent segment were eligible. Patients with
severe peripheral vascular disease or anticipated
difﬁculties with angiographic follow-up, as well as
those with severe systemic conditions or a life
expectancy <1 year, were excluded. Patients with
contraindications to aspirin or clopidogrel also were
not eligible (7,8,18,21). Written informed consent was
obtained from all patients.
Twenty-three university hospitals in Spain partic-
ipated in this trial (Online Appendix). Telephone-
based randomization was performed at the
coordinating center (Clínico San Carlos, University
Hospital, Madrid) using a computer-generated code.
Randomization (1:1) was stratiﬁed according to ISR
length (#10 mm or >10 mm) and lesion location
(intrastent- vs. edge-ISR) (22). Clinical and angio-
graphic outcome assessors were masked to the allo-
cated treatment strategy; patients and treating
physicians were not.
Data monitoring, collection, management, and an-
alysis were organized by the coordinating center (22).nrestricted grant from B. Braun Surgical and Abbott
in the design of the study, data analysis, data inter-
. Dr. Moreno has received lecture fees from Abbott
levant to the contents of this paper to disclose.
ntin Fuster.
2015, accepted April 20, 2015.
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25The study was an investigator-driven initiative orga-
nized under the auspices of the Working Group on
Interventional Cardiology of the Spanish Society
of Cardiology using unrestricted research grants from
B. Braun Surgical and Abbott Vascular. The study
followed the provisions of the Declaration of Helsinki
and was approved by the Institutional Ethics Com-
mittee of all corresponding centers. The primary
endpoint was the comparison between the 2 arms of
the in-segment minimal lumen diameter (MLD) at the
9-month follow-up (22).
INTERVENTIONS. Patients received pre-procedural
aspirin and clopidogrel, with a loading dose (300 to
600 mg) administered to clopidogrel-naive patients.
Unfractionated heparin was used during the proce-
dure with an initial bolus of 100 mg/kg, followed by
additional boluses as necessary, to maintain an acti-
vated clotting time >250 s. The protocol mandated
careful lesion pre-dilation. Initially, lesions were
dilated with relatively short balloons at low pressures
to avoid damage to the adjacent coronary segment.
Then high pressures were systematically recom-
mended. If underexpanded stents were identiﬁed, the
use of short noncompliant balloons at very high
pressures was recommended (22). Once adequate
lesion pre-dilation was obtained, patients received the
allocated treatment, with special attention paid to
prevent “geographic miss” phenomena. In patients
allocated to DEB (SeQuent Please, B. Braun Surgical,
Melsungen, Germany), a 1.1:1 balloon-to-artery ratio
was selected using nominal pressures (12 to 14 atm) for
60 s. Crossover to bailout stenting was strongly
discouraged in this arm. However, crossover was
allowed in cases of dilation failure (>50% residual
diameter stenosis) or major (>type C) residual dis-
sections. Alternatively, EES (Xience Prime, Abbott
Vascular, Abbott Park, Illinois) were deployed using a
1.1:1 ﬁnal balloon-to-artery ratio and high (>14 bar)
pressures. Although post-dilation with noncompliant
balloons was recommended, the ﬁnal strategy was at
the operator’s discretion. However, the protocol
emphasized the need for post-dilation using non-
compliant balloons at very high pressures in all pa-
tients with suboptimal angiographic results or
residual underexpanded stents (22). Special care
was indicated to ensure that all high-pressure bal-
loon inﬂations were performed within the stent
boundaries.
Intracoronary imaging techniques (intravascular
ultrasound or optical coherence tomography) were
recommended in the protocol to: 1) assess the un-
derlying substrate and stent expansion; and 2) opti-
mize procedural results. Selection of technique andthe criteria used for ﬁnal optimization were left to
the operator. Patients treated under intravascular
guidance were included in pre-deﬁned imaging
substudies.
Enzymatic determinations were serially obtained,
including serum creatine kinase (with MB analyses
for values above the local upper normal limits) and
troponin levels. Likewise, 12-lead electrocardiograms
were obtained every 8 h during the ﬁrst day (22).
Clopidogrel (75 mg/day) was recommended for 1 year
after EES implantation but only for 3 months
in patients treated with DEB. Aspirin was used
indeﬁnitely.
FOLLOW-UP. Patients were followed at 6 to 9 months
and 1 year; they will be followed annually for 5 years.
Late angiographic follow-up was scheduled at 6 to
9 months, but coronary angiography was performed
earlier in patients with recurrent symptoms. Elec-
tronic case report forms were completed by the local
investigators, monitored, and submitted to the coor-
dinating center, where data were critically reviewed
for consistency. Missing data requests and speciﬁc
queries were sent to sites when necessary. The vali-
dated dataset was entered into a dedicated relational
database used in all previous RIBS studies (7,8,18,21).
Source documents were obtained for all patients with
adverse events. Clinical events (death, MI, and target
vessel revascularization [TVR]) were adjudicated
by an independent and blinded clinical events com-
mittee. Deaths were considered cardiac unless a
noncardiac cause could be clearly established; MI
diagnosis remained unchanged in the RIBS trials
(7,8,18,21) and included 2 of the following: prolonged
(>30 min) chest pain; rise in creatine kinase levels
more than twice the local upper normal values (with
abnormal MB fraction); and development of new
persisting ischemic electrocardiogram changes (with
or without new pathological Q-waves). By protocol,
all repeated interventions had to be clinically justiﬁed
(angina, objective evidence of ischemia, or fractional
ﬂow reserve <0.80). In patients requiring TVR,
all corresponding angiograms were carefully ana-
lyzed at the core laboratory to identify the repeat
revascularization’s exact location (in-segment vs.
a different segment). The Academic Research
Consortium deﬁnition was used to assess stent
thrombosis (23).
ANGIOGRAPHIC ANALYSIS. All angiograms were
analyzed at the central core laboratory by trained and
blinded personnel using standard methodology
(7,8,18,21). Lesion morphology was assessed using the
Mehran (24) and American College of Cardiology/
American Heart Association (25) angiographic
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26classiﬁcations. Following administration of intra-
coronary nitroglycerin, 3 orthogonal projections were
selected, taking care to avoid vessel foreshortening
and overlap of major side branches. Matched pro-
jections were repeated after interventions and at late
follow-up. A validated automatic edge-detection
system (CAAS II System, Pie Medical, Maastricht, the
Netherlands) was used for quantitative analysis
(18,21,22). Both in-lesion (narrowing and references
automatically identiﬁed by the system) and in-
segment (lesion þ complete treated segment þ 5-mm
adjacent margins) quantitative analyses were per-
formed. Reference vessel diameter, MLD, and percent
diameter stenosis were measured pre-procedurally,
post-procedurally, and at late follow-up. Acute
lumen gain, net gain, late loss, loss index, and
binary restenosis rate (>50% diameter stenosis) were
determined.
SAMPLE SIZE. Immediately after conventional
balloon angioplasty, an MLD of 2.2  0.5 mm was
found in the RIBS I and II trials (7,8). A previous study
of DEB for BMS-ISR showed late lumen loss of 0.17 
0.42 mm (12). However, larger late loss was antici-
pated in patients with DES-ISR. In a previous acute
mechanistic study, we found an “early lumen loss” of
0.4 mm after conventional balloon angioplasty (26).
Likewise, ISAR-DESIRE 3 (Intracoronary Stenting and
Angiographic Results: Drug Eluting Stents for In-
Stent Restenosis 3), recently reported a late loss of
0.37 mm after DEB for DES-ISR (17). Assuming the
worst case scenario (late lumen loss of 0.4 mm), anow Chart
t
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nts (Pts) with drug-eluting stent in-stent restenosis (DES-ISR) from
were randomly allocated to drug-eluting balloons (DEB) or
tents (EES). Angio ¼ angiographic; FU ¼ follow-up; ISR ¼ in-stent
antitative coronary angiography; Rx ¼ randomization.MLD of 1.80  0.6 mm at follow-up was estimated in
the DEB arm (22).
Results of EES in patients with DES-ISR were not
available when the trial was designed so sample size
calculation required major assumptions. Again, based
on the previous RIBS studies, we assumed an MLD of
2.6  0.4 mm immediately after stent implantation
(7,8). In patients with BMS-ISR treated with
sirolimus-eluting stents (SES), the RIBS II study
showed a late loss of 0.13 mm (8), whereas the ISAR-
DESIRE 1 study showed a late loss of 0.32 mm (9).
However, in patients with DES-ISR, the ISAR-DESIRE
2 trial reported larger late loss (0.4 mm) using ﬁrst-
generation DES (10). Assuming a worst-case sce-
nario, a late loss of 0.6 mm after EES was assumed
for the current study. Accordingly, an MLD of 2.0
 0.6 mm at follow-up was estimated in the EES
arm (22).
Using a superiority design (null hypothesis of EES
not different than DEB), with an 80% power and an
alpha value of 5%, 142 patients per arm were required
to prove superiority of EES over DEB (comparison of
means in MLD at follow-up; STATA version 11.0,
StataCorp LP, College Station, Texas). To compensate
for losses in angiographic follow-up (assumed <10%),
310 patients (155 per arm) needed to be enrolled (22).
STATISTICAL ANALYSES. Categorical data (values
and percentages) were compared with the chi-square
or Fisher exact test. The Kolmogorov-Smirnov test
was used to determine normality in data distribution.
Continuous data are presented as mean  SD or me-
dian and interquartile range, as required, and were
compared using the Student t test or Mann-Whitney
test. Main effect estimates are presented with their
95% CI. Event-free survival was estimated from
Kaplan-Meier curves and compared with the log-rank
and Breslow exact tests. Hazard ratios and 95% con-
ﬁdence intervals were assessed using Cox models and
compared with the Wald test. Results of main
outcome measure were examined according to 10 pre-
speciﬁed, relevant clinical and angiographic variables
previously detailed in other RIBS trials (7,8,18,21).
Interactions were tested by 2-way analysis of vari-
ance. Analyses were performed according to the
intention-to-treat principle, unless otherwise speci-
ﬁed. SPSS Statistics version 15.0 (SPSS Inc., Chicago,
Illinois) was used. A p value <0.05 was considered
statistically signiﬁcant.
Authors from the coordinating center (F.A.,
M.J.P-V., A.C., C.F.) had full access to the study’s
entire dataset, performed the statistical analysis, and
decided to submit the study for publication and take
full responsibility in this regard. Statistical analyses
TABLE 1 Baseline Clinical, Angiographic, and
Procedural Characteristics
DEB (n ¼ 154) EES (n ¼ 155) p Value
Age, yrs 66  10 66  10 0.56
Female 27 (18) 25 (16) 0.74
Risk factors
Diabetes mellitus 75 (49) 66 (43) 0.28
Insulin dependent 26 (17) 29 (19) 0.76
Hyperlipidemia 110 (71) 121 (78) 0.18
Hypertension 110 (71) 121 (78) 0.18
Ever smoked 89 (58) 87 (56) 0.77
Clinical features 0.86
Unstable angina 80 (52) 79 (51)
Stable angina/silent
ischemia
74 (48) 76 (49)
Previous myocardial
infarction
73 (47) 77 (50) 0.69
Previous bypass surgery 16 (10) 17 (11) 0.87
>1 stent intervention on
target lesion
17 (12) 18 (12) 0.87
Time to restenosis, days 520 (286–1,417) 550 (279–1,670) 0.97
Ejection fraction, % 58  12 59  11 0.93
Target artery 0.76
Left anterior
descending
77 (50) 71 (46)
Left circumﬂex 27 (18) 34 (22)
Right coronary 43 (28) 45 (29)
Saphenous vein graft 7 (4) 5 (3)
DES type 0.92
Limus DES 111 (72) 113 (73)
Paclitaxel DES 39 (25) 37 (24)
Unknown* 4 (3) 5 (3)
Procedural characteristics
Length of previous
stent, mm
21  7 21  7 0.69
Cutting/scoring balloon
pre-dilation
7 (4) 5 (3) 0.66
Length of current
EES/DEB, mm
19  6 19  8 0.75
Maximal pressure, atm 18  4 20  4 0.001
Total inﬂation time, s† 115  44 59  43 0.001
Balloon-to-artery ratio 1.22  0.2 1.17  0.2 0.05
Crossover 5 (3) 1 (0.6) 0.12
Angiographic success 154 (100) 155 (100) 1
Values are mean  SD, n (%), or median (interquartile range). *DES conﬁrmed, but
the precise type of DES unknown. †Total inﬂation time represents the sum of the
time of all dilations at the target site.
DEB ¼ drug-eluting balloon(s); DES ¼ drug-eluting stent(s); EES ¼ everolimus-
eluting stent(s).
TABLE 2 Angiographic Results
DEB EES p Value
Qualitative features 154 155
Mehran I, II, III–IV 97 (63), 53 (34), 4 (3) 99 (64), 44 (28),12 (8) 0.09
B2–C lesion 69 (45) 69 (45) 0.96
Edge-ISR 36 (23) 39 (25) 0.71
Quantitative features
Pre-procedure 154 155
RVD, mm 2.59  0.5 2.67  0.5 0.21
MLD, mm 0.79  0.4 0.75  0.4 0.37
Stenosis, % of lumen diameter 69  17 72  15 0.17
Lesion length, mm 10.4  5.6 10.7  5.4 0.56
Diffuse lesions >10 mm 58 (38) 64 (42) 0.48
Post-procedure (in segment) 154 155
RVD, mm 2.58  0.5 2.55  0.5 0.64
MLD, mm 2.10  0.4 2.22  0.5 0.04
Stenosis, % of lumen diameter 18  10 13  11 <0.001
Acute gain, mm 1.31  0.5 1.48  0.6 0.006
Post-procedure (in lesion) 154 155
RVD, mm 2.64  0.5 2.70  0.5 0.30
MLD, mm 2.20  0.4 2.49  0.5 <0.001
Stenosis, % of lumen diameter 16  10 8  11 <0.001
Acute gain, mm 1.40  0.5 1.75  0.6 <0.001
At follow-up (in segment) 139 133
RVD, mm 2.60  0.6 2.66  0.6 0.38
MLD, mm* 1.80  0.6 2.03  0.7 0.004
Stenosis, % of lumen diameter 30  22 23  22 0.009
Restenosis 27 (19) 15 (11) 0.06
Late loss, mm 0.30  0.6
0.14 (0.18 to 0.65)
0.18  0.6
0.06 (0.20 to 0.40)
0.06
Loss index 0.22  0.5
0.13 (0.14 to 0.44)
0.03  0.6
0.04 (0.14 to 0.28)
0.03
Net gain, mm 1.01  0.7 1.28  0.7 0.002
At follow-up (in lesion) 139 133
RVD, mm 2.67  0.6 2.76  0.5 0.17
MLD, mm 1.89  0.7 2.20  0.7 <0.001
Stenosis, % of lumen diameter 28  22 19  23 0.001
Restenosis 25 (18) 13 (10) 0.048
Values are n, n (%), mean  SD, or median (interquartile range). *Primary endpoint of the study.
ISR ¼ in-stent restenosis; MLD ¼ minimal lumen diameter; RVD ¼ reference vessel diameter;
other abbreviations as in Table 1.
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27were performed at the clinical epidemiology depart-
ment at the coordinating center.
RESULTS
From January 2010 to August 2013, a total of 309 pa-
tients with DES-ISR were enrolled and randomly
assigned to DEB (n ¼ 154) or EES (n ¼ 155) (Figure 1).
Baseline clinical and angiographic characteristicswere well balanced in the 2 groups (Table 1), and
procedural characteristics were similar. Although
both arms used very high dilation pressures, higher
pressures were used in the EES arm. Angiographic
success was obtained in all patients (100%). Crossover
was required in 5 patients (3%) in the DEB arm
(4 treated with EES and 1 with BMS) and in 1 patient
(0.6%) in the EES arm (the stent could not be
advanced to the lesion site; therefore, a DEB was used
instead).
During hospitalization, 1 patient with severe left
ventricular dysfunction suffered an anterior non–
Q-wave MI and died in cardiogenic shock 4 days after
an angiographically successful DEB treatment of a
lesion in the left anterior descending coronary artery.
FIGURE 2 Primary
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28Two additional patients developed a non–Q-wave MI
despite angiographic success: 1 patient with ISR on a
saphenous vein graft treated with EES and 1 patient in
whom DEB treatment was complicated with a ﬂow-
limiting coronary dissection that ﬁnally required
crossover to EES. No other major in-hospital compli-
cations occurred.
Baseline angiographic characteristics were similar
in both arms (Table 2). Immediately after the proce-
dure, EES patients obtained a signiﬁcantly larger
acute lumen gain and ﬁnal MLD, plus showed lower
residual stenosis (Table 2). Late angiographic follow-
up (median 247 days in the DEB group and 248 days
in the EES group; p ¼ 0.95) was obtained in 272
patients (90% of those eligible). In-segment MLD at
follow-up (primary study endpoint) was signiﬁcantly
larger in the EES arm (2.03  0.7 mm vs. 1.80  0.6
mm; p < 0.01; absolute mean difference 0.23 mm;
95% CI: 0.07 to 0.38) (Table 2, Figure 2). Notably, the
analysis of the primary endpoint according to 10 pre-
speciﬁed variables showed consistent results in all
subgroups without any signiﬁcant interaction after
formal testing (Figure 3). Other late angiographic
ﬁndings, including percent diameter stenosis (Central
Illustration), net angiographic gain, and loss index,
were signiﬁcantly better in the EES arm. There were
strong trends for reductions in the binary restenosis
rate (11% vs. 19%; p ¼ 0.06) and in angiographic late
loss (median 0.06 mm vs. 0.14 mm; p ¼ 0.06) in the
EES group (Table 2). Importantly, based on in-lesionEndpoint: MLD
1 2 3 4
MLD (mm)
FU POST
p = 0.04p = 0.004
DEB
EES
y distribution curves compared minimal lumen diameter (MLD) be-
ated to DEB and EES at late angiographic FU (dashed lines). POST ¼
tervention; PRE ¼ before intervention; other abbreviations as inanalysis, all major late angiographic ﬁndings
(including binary restenosis rate and late loss) were
signiﬁcantly better in the EES arm (Table 2).
One-year clinical follow-up was obtained in all
309 patients (100%). Clinical events during the ﬁrst
year are summarized in Table 3. During this time,
7 patients died (3 in the DEB arm and 4 in the EES
arm), 4 of them from cardiac causes (2 in each arm).
Seven patients experienced an MI (5 in the DEB arm
and 2 in the EES). Deﬁnitive stent thrombosis
occurred in 3 patients (2 in the DEB arm and 1 in the
EES). Importantly, those cases in the DEB arm were
patients who ﬁrst developed ISR that was treated
with DES and subsequently experienced stent
thrombosis. There were 2 additional cases of probable
stent thrombosis (1 in each arm) that presented as a
late MI. Target lesion revascularization (TLR) was
required in 27 patients; 2 underwent coronary surgery
(1 in each arm) and 25 percutaneous intervention
(19 in the DEB arm and 6 in the EES arm). EES use
signiﬁcantly and consistently reduced TVR and TLR
rates (Table 3, Central Illustration, Figure 4). A clinical
justiﬁcation for TLR could be documented in all but
3 patients who nevertheless presented with severe
(2 functional occlusions) angiographic ISR on visual
assessment. The main clinical outcome measure (car-
diac death, MI, and TVR) was signiﬁcantly reduced in
the EES arm (Central Illustration). Angiographic and
clinical results in the as-treated analysis were similar
to those in the intention-to-treat analysis.
DISCUSSION
This is the ﬁrst randomized clinical trial comparing
the results of DEB with those of second-generation
DES in patients presenting with DES-ISR. These in-
terventions constitute the best currently available
therapeutic modalities for these challenging patients
(3). In this study, we selected a speciﬁc DEB (that uses
iopromide as a hydrophilic spacer) that has consis-
tently demonstrated efﬁcacy in patients with ISR
(11–18). Likewise, we selected EES as the second-
generation DES because it has clearly demonstrated
signiﬁcant improvements in late angiographic and
clinical outcomes compared with ﬁrst-generation DES
(19,20). The results of the present study demon-
strated that in patients presenting with DES-ISR, EES
provided signiﬁcantly better late angiographic results
compared with DEB. These included in-segment MLD
and other major secondary late angiographic param-
eters. Notably, the superior late angiographic ﬁndings
of EES were consistent using both in-segment
and in-lesion analyses, suggesting that ﬁnal results
were not affected by edge-related problems. The
FIGURE 3 AMD in MLD in Pre-Speciﬁed Subgroups
All
Age ≥65 yrs
Age <65 yrs
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Male
Diabetes
No Diabetes
UA
No UA
Time RE (<6 mo)
Time RE (≥6 mo)
LAD
No LAD
Vessel <3 mm
Vessel ≥3 mm
Diffuse (>1O mm)
Focal (<10 mm)
Edge ISR
No Edge ISR
B/A ≥1.1
B/A <1.1
0.23
0.19
0.27
0.12
0.25
0.08
0.34
0.16
0.29
0.21
0.24
0.15
0.29
0.27
0.06
0.12
0.35
0.27
0.21
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All interactions (NS)
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272
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44
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124
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0.004
0.08
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0.001
0.21
0.003
0.43
0.16
0.02
0.001
0.76
0.34
0.001
0.12
0.02
0.01
0.21 0.15
0.005
In terms of absolute mean difference (AMD) in MLD, EES were superior to DEB overall, and
all interactions within 10 pre-speciﬁed subgroups were not signiﬁcant. p Values indicate
the difference between strategies. B/A ¼ balloon-to-artery ratio; LAD ¼ left anterior
descending coronary artery; RE ¼ restenosis; UA ¼ unstable angina; other abbreviations as
in Figures 1 and 2.
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29meticulous protocol used in both arms to prevent
damaging adjacent coronary segments and avoid
geographic miss phenomena may have been beneﬁ-
cial in this regard.
The superior late angiographic ﬁndings achieved
with EES stemmed partially from better acute proce-
dural results compared with the DEB arm. This was
found consistently in all previous studies comparing
stent- and balloon-based strategies for ISR
(7–9,12,17,18). However, despite using very high
dilation pressures, the acute lumen gain and MLD
obtained immediately post-procedure were lower
than anticipated (22). Although affecting both arms,
this problem was particularly evident in the EES
group. The reason for this remains speculative but
may be secondary to the unfavorable substrate of
DES-ISR, the presence of resistant DES under-
expansion, or both. The underlying pathological
substrate of DES-ISR appears to be particularly
adverse and frequently includes neoatherosclerosis
(3,27,28). On the other hand, superior late angio-
graphic results with EES were also a consequence of
the profound antirestenotic efﬁcacy of this new-
generation DES, even in this adverse anatomic
setting. Indeed, the late loss and loss index were
favorable after EES for both in-segment and in-lesion
analysis. This is relevant because the classic angio-
graphic dictum “the more you gain, the more you
lose” (29) was not observed in the present study,
likely a result of the unique antiproliferative efﬁcacy
of EES. Therefore, EES not only led to larger acute
angiographic gain but also showed less late loss at
follow-up. Additionally, our ﬁndings were consistent
for 10 pre-speciﬁed subgroups, emphasizing that the
relative efﬁcacy of EES compared with DEB was
maintained in diverse clinical and angiographic
scenarios.
Importantly, superior late angiographic ﬁndings
obtained with EES translated into signiﬁcantly better
long-term clinical outcomes (Central Illustration). The
main clinical outcome measure was signiﬁcantly
reduced in the EES arm, mainly driven by a signiﬁcant
reduction in repeat revascularization. Indeed, both
TVR and TLR were signiﬁcantly reduced in the EES
arm. Notably, in our study, repeated coronary re-
vascularizations had to be clinically indicated and not
just a result of the “oculo-stenotic” reﬂex. Finally,
episodes of stent thrombosis were rare and similar in
the 2 arms, suggesting that both strategies are safe in
this adverse anatomic setting. Notably in the DEB
arm, stent thrombosis was found in only 2 patients
who had recurrent ISR treated with DES implantation,
but no patient suffered an acute vessel closure
directly after DEB treatment.PREVIOUS STUDIES. Several randomized clinical tri-
als have demonstrated the value of ﬁrst-generation
DES in patients presenting with BMS-ISR or DES-ISR.
In patients with BMS-ISR, the RIBS II study (8)
demonstrated the superiority of SES compared with
balloon angioplasty, whereas the ISAR-DESIRE 1 study
(9) demonstrated that both SES and paclitaxel-based
CENTRAL ILLUSTRATION Efﬁcacy of EES Versus DEB on In-Stent Restenosis
Alfonso, F. et al. J Am Coll Cardiol. 2015; 66(1):23–33.
Treatment of in-stent restenosis from drug-eluting stents remains challenging. This study evaluated the efﬁcacy of newer-generation everolimus-eluting
stents (EES) compared with drug-eluting balloons (DEB). Late angiographic ﬁndings, such as these cumulative frequency distribution curves displaying
percent diameter stenosis, were signiﬁcantly better in the EES arm (top). Patients randomized to EES also demonstrated signiﬁcantly better clinical
outcomes as seen in the Kaplan-Meier estimates of event-free survival from major adverse cardiac events (MACE) (bottom). FU ¼ at late angiographic
follow-up (top, late angiographic; bottom, 1 year clinical follow-up); MI ¼ myocardial infarction; POST ¼ immediately after intervention; PRE ¼ before
intervention; RE ¼ binary restenosis rate (<50% diameter stenosis); RR ¼ relative risk; TVR ¼ target vessel revascularization.
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TABLE 3 Major Adverse Clinical Events
DEB (n ¼ 154) EES (n ¼ 155) p Value* RR (95% CI)
Hospital events
Death 1 (0.6) 0 (0.0) 0.5 —
Cardiac death 1 (0.6) 0 (0.0) 0.5 —
MI 2 (1.3) 1 (0.6) 0.62 0.75 (0.33–1.67)
TLR 0 (0.0) 0 (0.0) — —
TVR 0 (0.0) 0 (0.0) — —
Coronary angioplasty 0 (0.0) 0 (0.0) — —
Coronary surgery 0 (0.0) 0 (0.0) — —
Composite MACE 2 (1.3) 1 (0.6) 0.62 0.75 (0.33–1.67)
HR (95% CI)
Events at 9 months
Patients on DAPT at 9 months 127 (84) 152 (99) 0.001
Death 3 (2.0) 3 (2.0) 0.99 0.99 (0.20–4.91)
Cardiac death 2 (1.3) 1 (0.6) 1.0 0.49 (0.045–5.44)
MI 5 (3.0) 2 (1.3) 0.24 0.40 (0.08–2.04)
TLR 19 (12.0) 7 (5.0) 0.01 0.35 (0.15–0.83)
TVR 22 (14.0) 12 (8.0) 0.06 0.52 (0.26–1.05)
Composite MACE (with TLR) 23 (15.0) 9 (6.0) 0.008 0.37 (0.17–0.80)
Composite MACE (with TVR) 26 (17.0) 14 (9.0) 0.04 0.51 (0.27–0.98)
Events at 1 year
Patients on DAPT at 1 year 88 (64.0) 109 (79.0) 0.007
Death 3 (1.9) 4 (2.6) 0.71 1.32 (0.30–5.90)
Cardiac death 2 (1.3) 2 (1.3) 0.99 0.99 (0.14–7.02)
MI 5 (3.2) 2 (1.3) 0.24 0.40 (0.08–2.04)
TLR 20 (13.0) 7 (4.5) 0.007 0.33 (0.14–0.79)
Coronary angioplasty TLR 19 (12.3) 6 (3.9) 0.005 0.30 (0.12–0.75)
Coronary surgery TLR 1 (0.6) 1 (0.6) 0.99 0.99 (0.06–15.9)
TVR 25 (16.2) 13 (8.4) 0.03 0.49 (0.25–0.97)
Composite MACE (with TLR) 24 (16.0) 10 (7.0) 0.009 0.39 (0.19–0.83)
Composite MACE (with TVR)† 28 (18.0) 16 (10.0) 0.042 0.58 (0.35–0.98)
Values are n (%). Patients with>1 event are counted only once for the composite clinical endpoint, although each
event is listed separately in the corresponding category. *Cox analysis. †Primary combined clinical outcome
measure.
DAPT ¼ dual antiplatelet therapy; HR ¼ hazard ratio (events at follow-up); MACE ¼ major adverse cardiac
event(s) (cardiac death, MI, TLR/TVR); MI ¼ myocardial infarction; RR ¼ risk ratio (hospital events); TLR ¼ target
lesion revascularization; TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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31DES were superior to balloon angioplasty. Subse-
quently, the ISAR-DESIRE 2 trial (10) suggested that
in patients with SES-ISR, use of paclitaxel-based
DES or another SES provided comparable long-term
results. Likewise, many randomized clinical trials
have consistently demonstrated the efﬁcacy of DEB
in patients with BMS-ISR and DES-ISR (11–18). Over-
all, DEB provided superior results compared with
conventional balloon angioplasty and equivalent
results to those obtained with ﬁrst-generation DES.
Accordingly, recent revascularization guidelines have
suggested that both strategies (DEB and DES) may be
used in patients with ISR (class I, level of evidence
A for the 2 therapies) (30).
However, scant information exists on the relative
value of second-generation DES versus DEB in pa-
tients with ISR. In patients with BMS-ISR, the RIBS V
randomized study (18) recently demonstrated that
EES provided superior late angiographic results
compared with DEB; however, those improved late
angiographic ﬁndings failed to translate into a sig-
niﬁcant reduction in the clinical need for revascular-
ization during follow-up. Actually, both strategies
provided excellent angiographic results (including
very low late loss and single-digit rates of binary
restenosis) and satisfactory long-term clinical out-
comes (18). Another interesting mechanistic study
(using optical coherence tomography) suggested that
in patients with BMS-ISR, DEB are less effective
than EES (31).
A large observational study conﬁrmed that DEB
were also less effective in patients with DES-ISR than
in those with BMS-ISR (32). Although the reasons are
unclear, drug resistance or the presence of underlying
neoatherosclerosis (a relatively common ﬁnding in
patients with DES-ISR) have been proposed as po-
tential explanations (3). Recently, the ISAR-DESIRE 3
trial (17) compared the efﬁcacy of DEB, paclitaxel DES,
and conventional balloon angioplasty in patients with
limus DES-ISR. DEB provided equivalent clinical and
angiographic results to paclitaxel DES; both were
clearly superior to balloon angioplasty. This was an
elegant study design because only patients with SES
were included and the 2 active treatment arms used
the alternative drug (paclitaxel). Moreover, a control
arm (conventional balloon angioplasty) was available
for comparative purposes (17). The results of a recent
multicenter randomized trial that included 220 pa-
tients with DES-ISR (16) also demonstrated a rela-
tively large late lumen loss in the DEB arm (0.46 mm)
that, nevertheless, was noninferior to the paclitaxel
DES arm (0.55 mm). However, paclitaxel-eluting
stents remain ﬁrst-generation devices, meaning the
question of whether second-generation DES may besuperior to DEB in patients with DES-ISR remains of
utmost clinical interest.
Our study provides novel and clinically relevant
information for the treatment of patients with
DES-ISR. Although EES provided superior angio-
graphic and clinical results than DEB in this chal-
lenging setting, both therapeutic strategies produced
poorer results than those found in patients treated for
BMS-ISR. Importantly, we used the same inclusion/
exclusion criteria and methodology as in the RIBS V
trial that compared exactly the same strategies but in
patients with BMS-ISR (18). In the current study, late
loss seen after EES and DEB were 4-fold and 2-fold
higher, respectively, than those found in the RIBS V
study. Therefore, it appears that the uniquely adverse
scenario of DES-ISR was able to unravel the superi-
ority of EES compared with DEB, not only with regard
FIGURE 4 Freedom From TLR
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EES proved superior to DEB in reducing the need for target lesion revascularization (TLR).
Abbreviations as in Figure 1.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Everolimus-eluting stents provide greater freedom
from in-stent restenosis and late target lesion revas-
cularization than drug-eluting balloon angioplasty in
patients with in-stent restenosis of coronary drug-
eluting stents during near-term follow-up.
TRANSLATIONAL OUTLOOK: Longer-term
studies are needed to establish the optimum device
type for percutaneous coronary revascularization in
patients who develop in-stent restenosis of coronary
drug-eluting stents.
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32to late angiographic ﬁndings but also late clinical
outcomes.
STUDY LIMITATIONS. First, this remains a relatively
small study, even though it is one of the largest trials
in patients with DES-ISR, which fortunately remains a
relatively rare clinical entity (3,4). Further studies
with a large number of patients and longer follow-up
will be required to conﬁrm the clinical superiority of
EES over DEB in these patients. Second, we used a
speciﬁc DES only. Although it is tempting to suggest
that similar results might be obtained with other
second-generation DES, dedicated studies are
required to conﬁrm whether current ﬁndings consti-
tute a class effect that may be generalized to other
second-generation DES. Third, although we found
that EES were superior to DEB in most relevant clin-
ical and anatomic scenarios, our subgroup analysis
was largely underpowered to deﬁnitively answer this
important question. It remains possible, therefore,
that DEB are equivalent, or even superior, to
new-generation DES in speciﬁc patient subsets;
further studies are certainly warranted to address thisintriguing possibility. In clinical practice, DEB remain
very attractive in patients already presenting several
metal layers at the target site (recalcitrant ISR), in
those with relatively large side branches emerging
from the stent, and especially in patients unable to
maintain a prolonged dual antiplatelet regimen or at
high bleeding risk. Further studies are required to
unravel the subsets of patients with DES-ISR who
beneﬁt from the use of DEB. Finally, because this was
an open-label study, reinterventions might have been
favored in a speciﬁc treatment arm (17). However, our
protocol ensured that investigators only performed
clinically driven reinterventions, making this possi-
bility unlikely.
CONCLUSIONS
This study demonstrated the superior efﬁcacy of EES
compared with DEB in patients with DES-ISR. Our
ﬁndings strongly suggest that EES should be consid-
ered the therapy of choice in this vexing and chal-
lenging anatomic scenario.
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